CELLINK have been granted funding totalling €3,910,000 from the EU as a part of the Horizon 2020 program. CELLINK’s portion of the grant is €270,000

/in , /by

The REPAIR project aims to develop a new approach and clinically applicable method in cardiac contraction assistance. Current medical or surgical treatments cannot restore muscular contractility in heart failure and atrial fibrillation, two of the most common and serious cardiac diseases. A revolutionary approach would be to use smart materials to support or restore cardiac mechanical […]

Read more →

Synthego Raises $100 Million to Accelerate CRISPR Platform Scale-up in Response to Growing Demand

/in , , , /by

Major Life Sciences Investors Support Company’s Vision, Strengthen Its Position as the Leader in Genome Engineering for Rapid Therapeutic Discovery, Development and Manufacturing REDWOOD CITY, Calif. – Synthego, the genome engineering company, today announced that it raised $100 million in a Series D financing led by new investor Wellington Management, co-led by RA Capital Management and […]

Read more →

KromaTiD Awarded Direct to Phase II SBIR Grant by the National Human Genome Research Institute

/in , , /by

Longmont, CO – KromaTiD, Inc. announced today that it was awarded a Direct to Phase II SBIR grant by the National Human Genome Research Institute. The award supports development of a structural variant discovery platform – dGH DSCVR™ – enabling efficient discovery of genomic structural causes of rare disease and measurement of unwanted structural rearrangements […]

Read more →

MOBILion Closes $35M Series B Financing Round

/in , /by

aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery. Chadds Fords, PA. — MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, today announced a $35 million Series B funding round. The oversubscribed round was […]

Read more →

Mission Bio Raises $70M in Series C Funding Led by Novo Holdings to Accelerate Development of Cancer Therapies with Single-cell Multi-omics

/in /by

Capital raised will scale the Tapestri Platform to advance the development of precision medicine through improved biomarker discovery and drug development SOUTH SAN FRANCISCO, Calif. Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced $70 million in its Series C financing led by Novo Growth, the growth equity arm of […]

Read more →

DNA Script Expands Series B to $89M

/in , , , /by

Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™️ — the world’s first enzymatic DNA printer. PARIS and SOUTH SAN FRANCISCO, Calif.: DNA Script today announced a $50 million extension to its Series B financing, bringing the total investment of this round to $89 million. This oversubscribed round is led by […]

Read more →

Seer Announces $55M Financing Led by Fidelity Management and Research Company

/in , /by

— Funding to accelerate development and commercial launch of Proteograph™ suite of reagents, instrument and software products to deliver on untapped promise of proteomics — Redwood City, CA — Seer, Inc., a life sciences company focused on empowering exceptional scientific outcomes through the power of rapid, deep, unbiased proteomics information, today announced that it has raised […]

Read more →

Berkeley Lights Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

/in , /by

EMERYVILLE, Calif. — Berkeley Lights, Inc., (Nasdaq: BLI) a leader in Digital Cell Biology, today announced the closing of its initial public offering of 9,315,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,215,000 shares of common stock, at a public offering […]

Read more →

Berkeley Lights Announces Pricing of Initial Public Offering

/in , /by

EMERYVILLE, Calif., July 16, 2020 (GLOBE NEWSWIRE) — Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the pricing of its initial public offering of 8,100,000 shares of common stock at a public offering price of $22.00 per share. All of the shares of common stock are being offered by Berkeley Lights. In addition, Berkeley Lights has granted the underwriters a […]

Read more →

QIAGEN shareholders approve all agenda items related to acquisition by Thermo Fisher Scientific at Annual General Meeting

/in , /by

Venlo, the Netherlands  – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that its shareholders today approved all agenda items at the Company’s Annual General Meeting related to the proposed voluntary public takeover offer for the acquisition of all ordinary shares in QIAGEN by Quebec B.V., a wholly-owned subsidiary of Thermo Fisher Scientific Inc. (NYSE: TMO) for EUR 39 per […]

Read more →